SUDA Ltd (ASX: SUD) Acquires Novel Oro-Mucosal Anti-Cancer Agent

KEY TAKEAWAYS:

• UK-based Aluztra Bio Ltd will assign to SUDA Ltd. the pertinent global patents.
• Suda Ltd expresses procurement of novel anti-cancer treatments.
• The advancement of anti-cancer treatments via OroMista technology.

SUDA Limited (ASX: SUD), specialising in oro-mucosa drug delivery, has utilised its option to acquire the international intellectual property connecting to anagrelide, an anti-thrombotic agent, that has freshly shown promise as a novel anti-cancer agent. The option also entailing access to a number of budding analogues. Substantial to extensive due diligence over the past six months, SUDA strongly gathers that it can formulate an oro-mucosa spray of anagrelide by using the Company’s OroMist technology, which could potentially circumvent the side-effects associated with the molecule when administered as an oral capsule.

Following the terms of the agreement with the UK-based Aluztra Bio Ltd, Aluztra will allocate SUDA the pertinent global patents. Aluztra and its partners will be accredited to “a low single-digit percentage royalty on direct net sales or a share of income generated by SUDA from the commercialisation of an oro-mucosal spray of anagrelide. No other payments are due.”

Presently used as an anti-thrombotic agent to deduct increased levels of platelets is one remarkable mechanism of Anagrelide. Platelets have been identified by scientists that it also provides essential growth factors that nourish cancer cells and allow them to take hold and develop into tumours. Consequently, those patients with the highest platelet numbers are least likely to survive.

Anareglide has the inference to be enhanced as a potent anti-cancer agent. However, it is fundamentally limited in its presence by cardio-stimulatory side-effects. An oro-mucosal spray formulation of anagrelide could diminish these side-effects by preventing first pass generation of a significantly high potent cardio-excitatory metabolite of the drug in the liver.

It would be harmonious to such treatments by reduction of the platelet numbers (CO) resulting to deducing the proliferative and protective effect that platelets exhibit on metastatic cells and further rendering circulating cancer cells more susceptible to attack by the body’s own killer cells. Therefore, potentially provides a novel and highly advantageous first-in-class treatment option for cancer.

SUDA’s CEO and Managing Director, Mr Stephen Carter, expresses:

“We are excited by the anagrelide opportunity. Using our proprietary OroMista technology, we aim to formulate an oral spray of anagrelide that enables the active drug to be efficient across the oral mucosa membrane. This could provide a compelling new strategy for the treatment of solid tumours. There is substantial data in the literature to support the theory that non-enteral administration of anagrelide could avoid the dose-limiting cardiotoxicity associated with first-pass metabolism of this anti-cancer agent.”

About SUDA Ltd (ASX: SUD)

SUDA Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia.

Request Information